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ABSTRACT: MitoNEET is a protein that was identiﬁed
as a drug target for diabetes, but its cellular function as well
as its role in diabetes remains elusive. Protein pull-down
experiments identiﬁed glutamate dehydrogenase 1
(GDH1) as a potential binding partner. GDH1 is a key
metabolic enzyme with emerging roles in insulin
regulation. MitoNEET forms a covalent complex with
GDH1 through disulﬁde bond formation and acts as an
activator. Proteomic analysis identiﬁed the speciﬁc cysteine
residues that participate in the disulﬁde bond. This is the
ﬁrst report that eﬀectively links mitoNEET to activation of
the insulin regulator GDH1.

G

lutamate dehydrogenase 1 (GDH1, EC 1.4.1.3) is a key
enzyme at the center of cellular catabolism and
anabolism. It reversibly converts glutamate to α-ketoglutarate
and ammonia through the use of a NAD+ or NADP as a
cofactor. GDH1 primarily catalyzes the oxidation reaction in
mammals to contribute to the pool of α-ketoglutarate in the
Krebs cycle and, as such, is highly regulated by a number of
allosteric eﬀectors.1 The allosteric activator 2-aminobicyclo2,2,1-heptane-2-carboxylic acid (BCH) has recently been
shown to improve β-cell functions under diabetes-like
conditions.3 Conversely, a number of mutations of GDH1
have led to hyperinsulemia/hyperammonemia.2 We demonstrate here that the mitochondrial protein mitoNEET directly
interacts with and covalently modiﬁes GDH1 and acts as a new
allosteric activator of GDH1.
MitoNEET is a protein that was discovered in 2004 as a
target of the type 2 diabetes drug pioglitazone.4 The protein is a
homodimer with each monomer containing a [2Fe-2S] cluster
that is ligated by one histidine and three cysteine residues
(Figure 1A).5 MitoNEET is targeted to the mitochondria and is
localized primarily to the outer mitochondrial membrane facing
the cytosol. However, a signiﬁcant portion (up to 14.1%) is
localized to the mitochondrial interior.6
Since the discovery of mitoNEET, multiple putative
functions have been assigned to it, with each suggesting
interaction(s) with one or more protein binding partner(s).
Proposed functions include redox sensor, regulator of cellular
respiration, electron transfer protein, and an iron−sulfur cluster
transfer protein.9−6 The cellular levels of holo and apo
mitoNEET are unknown, and both species may be physiolog© XXXX American Chemical Society

Figure 1. (A) Crystal structure of mitoNEET. (B) Crystal structure of
GDH1. (C) SDSPAGE gel of the molecular mass ladder (lane 1),
mitoNEET (lane 2), and GDH1 (lane 3). The arrow denotes the
covalent dimer species. (D) SDS-PAGE gel of the covalent complex
formation showing the molecular mass ladder (lane 1), mitoNEET
with GDH1 without β-mercaptoethanol (BME) (lane 2), and
mitoNEET with GDH1 with BME (lane 3). The arrows denote
species present only the in absence of BME.

ically relevant. This is the ﬁrst report that links mitoNEET to
the activity of the insulin-regulating protein GDH1.
To identify protein-binding partners of mitoNEET, pulldown experiments conducted with cell lysates isolated from
mouse liver (Figure S1 of the Supporting Information) and
human hepatoma cells (HepG2) identiﬁed GDH1 from an ∼62
kDa band by proteomic analysis with 55 (q value of 3.37 ×
10−6) and 23 peptides (q value of 7.81 × 10−7) detected,
respectively.
The interactions of mitoNEET and GDH1 were characterized by gel electrophoresis. MitoNEET forms a homodimer
(Figure 1A) in crystal structures with a monomeric mass of
∼12 kDa, whereas GDH1 exists as a hexamer (Figure 1B) with
a monomeric mass of ∼56 kDa.1 The mass of both proteins was
analyzed by sodium dodecyl sulfate−polyacrylamide gel
electrophoresis (SDS−PAGE) under reducing and nonreducReceived: July 31, 2013
Revised: November 20, 2013
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Proteomic analysis identiﬁed only the Cys74mitoNEET −
Cys319GDH1 pair as the residues responsible for the mixed
disulﬁde bond formation (Figure 2A) through a mass shift of

ing conditions. Because there are no disulﬁde bonds in the
available crystal structure of either protein, the presence or
absence of a reductant should make no diﬀerence in the gel
results.
Interestingly, under nonreducing conditions, mitoNEET
migrated at two diﬀerent positions in the gel. One band was
in agreement with the expected size of ∼12 kDa; another band
had an apparent molecular mass of ∼24 kDa (Figure 1C, lane
2), while GDH1 was resolved as one band at ∼50 kDa (Figure
1C, lane 3). The ∼24 kDa band was conﬁrmed by proteomic
analysis to be a covalently linked mitoNEET homodimer not
observed in crystal structures.
Next, we incubated GDH1 with holo mitoNEET to
investigate possible covalent bond formation between the two
proteins. An ∼62 kDa band present on a SDS−PAGE gel was
dependent on the presence of both mitoNEET and GDH1 and
the absence of a reductant (Figure 1D, lane 2). The band was
sequenced using proteomic analysis and identiﬁed as a
mitoNEET−GDH1 complex. Because the ∼62 kDa band was
not present in samples that included β-mercaptoethanol (BME)
(Figure 1D, lane 3), we concluded the mechanism of
mitoNEET−GDH1 cross-linking is the formation of a disulﬁde
bond.
The only three cysteine residues in mitoNEET, Cys72,
Cys74, and Cys84, are three of the four residues that ligate the
[2Fe-2S] cluster.5 At least one of the cysteine residues must be
liberated from the coordinate covalent bond to an iron atom of
the [2Fe-2S] cluster to form an interdimer disulﬁde bond or a
mixed disulﬁde bond with GDH1. The shortest distance
between any two cysteine residues in crystal structures of
mitoNEET across the dimer interface is 12.6 Å (Figure S2A of
the Supporting Information).
The reactivity of the cysteine residues to form disulﬁde
bonds with themselves and/or other protein(s) suggests
mitoNEET is an important redox sensor in both the cytosol
and the mitochondrial matrix. The extent of dimer formation at
pH 8.5, analyzed by SDS−PAGE without a reductant, increased
with increasing concentrations of mitoNEET. With increases in
the concentration of mitoNEET from 97.8 μM to 195 μM to
390 μM, the covalent dimer band became more pronounced
(Figure S2B of the Supporting Information) and the bands
were quantiﬁed and showed a ratio of 1.2−1.5 monomers per
covalent dimer (Table S1 of the Supporting Information). The
covalent dimer band did not form under reducing conditions
with BME at any concentration that was investigated. The
occurrence of the covalently linked mitoNEET dimer is not due
to nonselective polymerization because no higher-order
oligomers were observed in the SDS−PAGE analysis.
Proteomic analysis of the ∼24 kDa band determined that the
disulﬁde bond forms between residues Cys83 and either Cys72
or Cys74 of mitoNEET (Figure S2D of the Supporting
Information). The same concentrations of mitoNEET were
also analyzed by native gel electrophoresis (Figure S2C of the
Supporting Information), and two higher-order oligomeric
bands (oligomer 1 and oligomer 2) were observed only in
samples not treated with BME. The bands were quantiﬁed
(Table S2 of the Supporting Information), and the noncovalent
dimer/(oligomer 1 + oligomer 2) ratio decreased as the
concentration of mitoNEET increased.
In comparison, GDH1 has six cysteine residues: Cys55,
Cys89, Cys115, Cys197, Cys270, and Cys319. As such, there
are 18 possible combinations of cysteines that could form
mixed disulﬁde bonds between CysmitoNEET and CysGDH1.

Figure 2. Characterizing the mitoNEET−GDH1 complex using (A)
proteomic identiﬁcation of the disulﬁde cysteine residues and (B)
SDS−PAGE analysis of the concentration dependence on complex
formation without (lanes 1−3) and with (lanes 4−6) the reductant
BME. The concentration of mitoNEET monomer was 195.6 μM
(lanes 1 and 3), 390.2 μM (lanes 2 and 4), and 780 μM (lanes 3 and
6) with a GDH1 monomer concentration of 180 μM. (C) Impact of
mitoNEET on GDH1 activity. The asterisk indicates signiﬁcant
diﬀerences between rates (P < 0.05).

463.55 Da of the GDH1 peptide. The mass shift corresponds to
the addition of the mitoNEET peptide 74CWR76 (Figure 2A, S3
of Supporting Information). Additionally, the concentration
dependence of the mitoNEET−GDH1 complex was investigated by increasing the mitoNEET monomer concentration
from 195.6 μM to 390 μM to 780 μM while keeping the
monomer GDH1 concentration at 180 μM (Figure 2B). The
percentage of cross-linked mitoNEET-GDH1 covalent complex
increased from 24.51% (195.6 μM mitoNEET) to 40.66% (780
μM mitoNEET) (Table S3 in the Supporting Information).
The lack of a mixed disulﬁde bond with GDH1 involving
Cys83mitoNEET is notable because it readily participates in the
homodimer disulﬁde bond. This result implies that there are
directing factors, such as steric or electrostatic interactions, that
either preclude Cys83mitoNEET or encourage Cys74mitoNEET to
react with Cys319GDH1. Two negatively charged aspartate
residues ﬂank Cys319GDH1, while Cys74mitoNEET is located next
to two positively charged arginine residues at positions n − 1
and n + 2. These charged residues for both proteins, near the
covalently bound cysteines, might control the formation of the
mixed disulﬁde bond. Cys319GDH1 was previously identiﬁed as
being modiﬁed by nucleotide analogues.10 Additionally, mutagenesis of Cys323GDH1, the analogous cysteine residue in the
human isoform, decreased kcat by approximately 10-fold relative
to that of the wild-type enzyme.11 Therefore, we investigated if
the reaction between mitoNEET and GDH1 impacts GDH1
activity, making mitoNEET a regulator of GDH1. GDH1
B
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(12) Allen, A., Kwagh, J., Fang, J., Stanley, C. A., and Smith, J. T.
(2004) Biochemistry 43, 14431−14443.

enzyme activity was determined by monitoring the production
of NADH at 340 nm (λ). The addition of mitoNEET in a
monomer equimolar amount increased the initial velocity of
GDH1 from 0.270 ± 0.003 to 0.428 ± 0.002 ΔAbs340/min for
GDH1 alone (Figure 2C).12
The increase in the activity of GDH1 resulted from the
formation of a mixed disulﬁde bond with mitoNEET because
the activation was negated with the inclusion of BME to the
GDH1−mitoNEET sample (0.226 ± 0.007 ΔAbs340/min).
This mirrors the result of the addition of the small molecule
BCH to GDH1.3 MitoNEET is a unique activator of GDH1 in
that it is a mitochondrial protein and exerts its action through a
redox-sensitive covalent bond. The ability of the cysteine
residues of mitoNEET to form disulﬁde bonds introduces
intriguing new evidence of the cellular functions of mitoNEET
as a redox sensor in addition to an activator of the insulin
regulator GDH1.
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